99.1 Press Release of NeoGenomics, Inc. dated June 1, 2018.

Exhibit Index

NEOGENOMICS INC Exhibit
EX-99.1 2 exhibit991asreleased0601.htm EXHIBIT 99.1 exhibit991asreleased0601 Exhibit 99.1 FOR IMMEDIATE RELEASE PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions Expanding global oncology testing for clinical trials WILMINGTON,…
To view the full exhibit click here

About NEOGENOMICS, INC. (NASDAQ:NEO)

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.